Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Rubin Acquires 21,529 Supernus Shares in Merger Exchange

Jonathan Rubin, SVP and Chief Medical Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership resulting from the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., effective November 2, 2026.

Nitish Kishor | 04 November 2026

Timothy Dec CFO Holdings Converted in Supernus Merger

Timothy C. Dec, Senior Vice President and Chief Financial Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes to his beneficial ownership resulting from the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. that became effective on November …

Shwetambri Chauhan | 04 November 2026

Patrick O'Kain Named COO at SVRN as Schwed Departs

SVRN, Inc. filed a Form 6-K on November 4, 2026, announcing the appointment of Patrick O'Kain as Chief Operating Officer effective November 3, 2026, following the resignation of David Schwed from that role.

Vinay Lochav | 04 November 2026

Mottola Gets Supernus Shares in Indivior Merger Conversion

Frank Mottola, SVP and Chief Technology Operations Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership of common stock and equity awards resulting from a merger that became effective on November 2, 2026.

Aditi Sarkar | 04 November 2026

Jack Khattar Gets Supernus Shares in Indivior Merger Nov 2

Jack A. Khattar, Chief Executive Officer and Director of Supernus, Inc. (NASDAQ:SUPN), filed a Form 4 on November 4, 2026, disclosing changes in his beneficial ownership of common stock and equity awards resulting from the November 2, 2026 effective date of the merger between …

Anjali Anand | 04 November 2026

Gemayel Receives 42,009 Supernus Shares in Merger Conversion

Director Georges Gemayel filed a Form 4 with the SEC on November 4, 2026, disclosing changes in beneficial ownership of Supernus, Inc. (NASDAQ:SUPN) common stock and equity awards resulting from the merger effective November 2, 2026, between Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.

Nitish Kishor | 04 November 2026

Bhatt Acquires Supernus Shares in Indivior Merger Conversion

Padmanabh P. Bhatt, SVP of IP and Chief Scientific Officer at Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership resulting from the November 2, 2026 merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc.

Vinay Lochav | 04 November 2026

Sensenig Gets Converted Awards After Supernus Merger

Director Bethany Sensenig filed a Form 4 with the SEC on November 4, 2026, disclosing the automatic conversion of her Supernus Pharmaceuticals equity awards into Supernus, Inc. equity awards following the completion of a merger on November 2, 2026.

Manish Choudhary | 04 November 2026

Carrolee Barlow's Holdings Converted in Supernus Merger

Director Carrolee Barlow filed a Form 4 with the SEC on November 4, 2026, disclosing changes in beneficial ownership of Supernus, Inc. common stock and equity awards resulting from the merger effective November 2, 2026, in which Indivior Pharmaceuticals, Inc. merged with Supernus Pharmaceuticals, …

Vinay Lochav | 04 November 2026

Carrolee Barlow Files Initial Ownership Statement With Zero Supernus Shares

Carrolee Barlow, a newly appointed director of Supernus, Inc., filed a Form 3 initial statement of beneficial ownership on November 4, 2026, disclosing no beneficial ownership of company securities as of the event date of November 2, 2026.

Aakashdeep | 04 November 2026
Support

Hi! How can we help you today?

Loading…